Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa

Haemophilia

Volumn 16, Issue 3, 2010, Pages 510-517

  Bolliger, D ^a,c   Szlam, F ^a   Molinaro, R J ^b   Escobar, M A ^d   Levy, J H ^a   Tanaka, K A ^a  

^a Department of Anesthesiology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

APCC; Aptamer; Factor IXa inhibition; Fibrinolysis; RFVIIa; Thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALTEPLASE; APTAMER; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; FLUORESCENCE; HEMOPHILIA; HUMAN; PLASMA; PRIORITY JOURNAL; SPIKE; THROMBIN TIME; THROMBOELASTOGRAPHY; VISCOELASTICITY;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FACTOR IXA; FACTOR VIIA; FACTOR VIII; FACTOR XA; FIBRINOLYSIS; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; THROMBIN;

EID: 77953565614     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02164.x     Document Type: Article

References (39)

1. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104:3858-64.
2. ten Cate H, Bauer KA, Levi M. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993, 92:1207-12.
3. Turecek PL, Varadi K, Gritsch H. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999, 77(Suppl. 1):72-9.
4. Turecek PL, Varadi K, Keil B. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003, 33:16-22.
5. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004, 2:1700-8.
6. Key NS, Aledort LM, Beardsley D. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998, 80:912-8.
7. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997, 77:1113-9.
8. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005, 11:100-6.
9. Astermark J, Donfield SM, DiMichele DM. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-51.
10. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007, 5:2408-14.
11. Lisman T, Mosnier LO, Lambert T. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002, 99:175-9.
12. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005, 131:645-55.
13. Tanaka KA, Szlam F, Rusconi CP, Levy JH. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 2009, 101:827-33.
14. Rusconi CP, Scardino E, Layzer J. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419:90-4.
15. Dyke CK, Steinhubl SR, Kleiman NS. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006, 114:2490-7.
16. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009, 102:793-9.
17. Taketomi T, Szlam F, Bader SO, Sheppard CA, Levy JH, Tanaka KA. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. Blood Coagul Fibrinolysis 2008, 19:135-41.
18. Hemker HC, Giesen P, Al Dieri R. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15.
19. Ingerslev J, Herlin T, Sorensen B, Clausen N, Chu KC, High KA. Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment. Haemophilia 2007, 13:334-6.
20. Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia 2008, 14:736-42.
21. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008, 14:782-6.
22. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001, 101:145-57.
23. Szlam F, Taketomi T, Sheppard CA, Kempton CL, Levy JH, Tanaka KA. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg 2008, 106:719-24.
24. Urano T, Ihara H, Suzuki Y, Takada Y, Takada A. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity. Semin Thromb Hemost 2000, 26:39-42.
25. Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998, 80:161-6.
26. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980, 65:290-7.
27. Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998, 273:27220-4.
28. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002, 100:148-52.
29. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993, 82:2433-41.
30. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006, 26:2445-53.
31. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997, 78:386-91.
32. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007, 27:683-9.
33. Lisman T, de Groot PG, Lambert T, Rojkjaer R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003, 1:2175-8.
34. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007, 137:158-65.
35. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988, 70:327-33.
36. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007, 5:812-7.
37. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009, 108:1447-52.
38. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009, 108:1433-46.
39. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002, 88:60-5.